Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus neoadjuvant TP chemotherapy followed by chemoradiotherapy in high-risk locally advanced cervical cancer
ChiCTR2600115927Phase 2Not yet recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Jan 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in Cervical Cancer (CC), sponsored by Women's Hospital, Zhejiang University School of Medicine. Primary endpoints: Progression-free survival (PFS), Objective response rate (ORR) after neoadjuvant therapy and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600115927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600115927.